DOI: http://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20192071

An analytical study on clinical patterns of herpes zoster in this era

Ravichandran Velappan, Sindhuja Ramasamy, Kamalanathan Nallu, Arulraja Ganapathi

Abstract


Background: Herpes zoster is a major health burden in all age groups. It is caused by reactivation of varicella zoster virus from dormant form. The immunity that plays a role in this reactivation is cell mediated immunity. Prodromal features like Fever, pain and itch are common before the onset of zoster rash. The most common complication associated with this disease is post-herpetic neuralgia. Complications associated with herpes zoster depend on the age, immune status, and the time of initializing treatment. Treatment with antiviral drugs within 72 hours of onset of rash onset has been shown to reduce severity and complications associated with zoster and the post-herpetic neuralgia.

Methods: We analysed 120 cases of herpes zoster patients who attended Dermatology OPD, in Chengalpattu Medical College Hospital from January 2018 to December 2018. The study design was descriptive study. A detailed history taking, thorough clinical examination and appropriate relevant investigations were done.

Results: The mean age group of the 120 patients (male-56, female-64) was 35 years. Segmental distribution: Thoracic-60%, cervical-6%, lumbosacral-2%, herpes zoster ophthalmicus-22%, herpes zoster oticus-10%. 34% were diabetic, 2% HIV, 4% following surgery/trauma, 10% on steroid therapy. 13% had history of native treatment. Prodromal symptoms in 34%, post herpetic neuralgia-60%, sepsis in 52%.

Conclusions: Herpes zoster occurs in dermatomes in which the rash of varicella achieves highest intensity. Herpes zoster can affect any age group with a higher incidence in elderly patients and in those with immuno-compromised status, treatment with antivirals within 72 hours of onset of rash has shown a reduction in severity and complications.


Keywords


Herpes zoster, Post herpetic neuralgia, Herpes zoster ophthalmicus

Full Text:

PDF

References


Gnann JW Jr., Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med. 2002;347:340‑6.

Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087-96.

Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD, et al. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol. 2010;48 Suppl 1:S2-7.

Ono F, Yasumoto S, Furumura M, Hamada T, Ishii N, Gyotoku T. Comparison between famciclovir and valacyclovir for acute pain in adult japanese immunocompetent patients with herpes zoster. J Dermatol. 2012;39:902‑8.

Schmid DS, Jumaan AO. Impact of varicella vaccine on varicella‑zoster virus dynamics. Clin Microbiol Rev. 2010;23:202-17.

Ogunjimi B, Van Damme P, Beutels P. Herpes zoster risk reduction through exposure to chickenpox patients: A Systematic multidisciplinary review. PLoS One. 2013;8:e66485.

Kim YJ, Lee CN, Lim CY, Jeon WS, Park YM. Population based study of the epidemiology of herpes zoster in Korea. J Korean Med Sci. 2014;29:1706‑10.

Koshy E, Mengting L, Kumar H, Jianbo W. Epidemiology, treatment and prevention of herpes zoster: A comprehensive review. Indian J Dermatol Venereol Leprol. 2018;84(3):251-62.

Stein AN, Britt H, Harrison C, Conway EL, Cunningham A, Macintyre CR, et al. Herpes zoster burden of illness and health care resource utilisation in the australian population aged 50 years and older. Vaccine. 2009;27:520‑9.

Li Y, An Z, Yin D, Liu Y, Huang Z, Xu. Disease Burden due to herpes zoster among population aged ≥50 years old in China: A community based retrospective survey. PLoS One. 2016;11:e0152660.

Chen SY, Suaya JA, Li Q, Galindo CM, Misurski D, Burstin S. Incidence of herpes zoster in patients with altered immune function. Infection. 2014;42:325-34.

Katz J, Cooper EM, Walther RR, Sweeney EW, Dworkin RH. Acute pain in herpes zoster and its impact on health‑related quality of life. Clin Infect Dis. 2004;39:342‑8.

Arvin AM. Varicella-zoster virus: overview and clinical manifestations. Semin Dermatol. 1996;15:4-7.

Kakourou T, Theodoridou M, Mostrou G. Herpes zoster. J Am Acad Dermatol. 1998;39:207-10.